11 policy trends implicit in the Report on the Work of the Government

On March 5, the fifth session of the 12th National People's Congress opened at the Great Hall of the People in Beijing, which heard and considered Premier Li Keqiang's report on the work of the government. In his government report, Premier Li Keqiang not only reviewed the fruitful results achieved in the field of health care in 2016, but also made important deployments for the work in 2017. 39 Pharmaceutical Jun after combing found that the contents of the field of medicine and health mainly include the following: 1, "three doctors" linkage, deepen the reform of the medical and health system
We will comprehensively push forward the comprehensive reform of public hospitals, abolish the drug fee al- and coordinate the reform of medical prices, personnel compensation, drug circulation and payment methods for medical insurance. We will launch a pilot project on the construction of various forms of medical complexes, and all three-level public hospitals should participate in and play a leading role in establishing an assessment and incentive mechanism to promote high-quality medical resources, enhance the capacity of grass-roots services, and facilitate the masses to seek medical treatment in close range.
39 Pharmaceutical Review: The three-doctor linkage is the core of medical reform. The reform of the three medical associations, together with the reform of the internal management system of hospitals, including personnel and remuneration systems, is, on the whole, conducive to solving the problem of difficult and expensive medical care, and at the same time, it is conducive to breaking down the mechanism of medical treatment, improving the enthusiasm of medical personnel, so that they can provide medical services to patients with greater peace of mind and diligence, so that the overall level of medical care can be improved.2, Healthy China, expand the scope of drug protection
promote the construction of a healthy China. The financial subsidy for medical insurance for urban and rural residents will be raised from 420 yuan per person per year to 450 yuan, and the standard of individual contributions will be raised simultaneously to expand the scope of drug protection.
39 Pharmaceutical Review: From the concept of "Healthy China" to this formulation has been written into the government work report for many years, to the "Healthy China 2030 Planning Outline" issued, to promote the construction of a healthy China, has been step by step up to the country's important strategic deployment. Driven by the policy, there are huge business opportunities in the health service sector. At present, the domestic service health industry size of 5 trillion, according to industry estimates, the size of the industry will reach 8 trillion in 2020, 16 trillion in 2030. In the future, China's health and related industries will become the Blue Sea market.3, medical information networking, to achieve off-site medical insurance settlement and medical insurance for major diseases
We will improve the insurance system for major diseases and improve the level of protection.
39 pharmaceutical review: to achieve the direct settlement of hospitalization costs, medical insurance for major diseases, the New Deal, for the common people, is definitely a big good. Because from then on, the insured cross-provincial medical treatment no longer need their full advance, but also to solve the major diseases of medical treatment. Pharmaceutical companies, including malignant tumors, severe cardiovascular diseases, kidney failure and other diseases, will also benefit. In the future, drugs for major diseases with remarkable efficacy and large interest space have better prospects for development.4, medical union, highlighting the "main force" status of public hospitals
fully launched various forms of medical union construction pilot, three-level public hospitals should all participate in and play a leading role, the establishment of high-quality medical resources to promote the up and down the assessment and incentive mechanism, enhance the capacity of grass-roots services, convenient for the masses to seek medical treatment.
39 Pharmaceutical Review: Medical reform is not only the reform of the supply side of medical services, but also the reconstruction of the medical service system. The construction of medical complex, play the leading role of three-level public hospitals, is not to allow large hospitals to expand again, run the horse occupied land, but to play the leading role of the government, the jurisdiction of medical resources through the medical complex to achieve organic integration, to pave the way for the implementation of graded diagnosis and treatment. The policy does not appear to have much to do with pharmaceutical companies, but in fact, it places higher demands on their operating models, market resources and operational capabilities. Pharmaceutical companies should do the layout early, develop effective business strategies, enhance public relations and comprehensive marketing capabilities, in order to cope with the coming changes.5, graded diagnosis and treatment, family contracting services up to more than 85% of the city
graded diagnosis and treatment pilot and family contracting services expanded to more than 85% of the city.
39 Pharmaceutical Review: The 2017 government work report again mentioned the graded diagnosis and treatment, in 2016 "about 70% of the cities to carry out the pilot of graded diagnosis and treatment on the basis of" continue to expand the scope of the pilot of graded diagnosis and treatment, and in the new medical reform into the 9th year, the first time "family contracted services" into the government work report. This is of great significance to patients with chronic diseases such as hypertension and diabetes. Innovative reform of incentive mechanism has been carried out in hospitals and primary health care institutions. At the same time, it also promoted the hospital management system, performance compensation system, medical insurance payment system, doctors multi-point practice and many other reforms.6, public health, increase costs and transparency
to continue to raise the standard of subsidies for basic public health services. Respond to public health events in a timely, transparent and effective manner.
39 Pharmaceutical Review: Major infectious disease outbreaks, unexplained diseases, major food and occupational poisoning and other public health events that seriously affect public health must be made public, which to some extent puts forward new requirements for prevention and control.7, doctor-patient relationship, protect and mobilize the enthusiasm of medical personnel
protect and mobilize the enthusiasm of medical personnel. Build a harmonious doctor-patient relationship.
39 Pharmaceutical Review: At present, the number of outpatients in the country's triple-A hospitals is huge, patients only spend two or three hours in line registration time, which is ultimately because of the scarcity of medical resources in Our country. In the future, hospitals need to do their best to treat patients' diseases, but patients should also recognize that doctors are not a 10-umn's reality, and should not be treated with less than ideal results to violently harm doctors. When there are medical accidents and violent attacks on doctors, the law should play a role, not a problem., comprehensive two-child, strengthen reproductive health care services
adapt to the implementation of a comprehensive two-child policy, strengthen reproductive health care services.
39 Pharmaceutical Review: With the introduction of the national two-child policy, the number of newborns is expected to rise from 16 million per year in the past to 20 million, which is not only related to the needs of pediatricians, pediatric medical institutions and children's medication is also facing great challenges. At present, China's children's medicine is still faced with a small variety, lack of dose specifications and incomplete drug information and other issues, tailor-made children's medicine is imminent. Therefore, we should pay more attention to the safe drug use of children as a special group, improve the guidance of the whole society on the safe drug use of children, and pharmaceutical enterprises should make great efforts to tailor the appropriate dosage forms and specifications for children.9, Traditional Chinese medicine, support the development of Traditional Chinese medicine, ethnic medicine.
support the development of Chinese medicine and ethnic medicine.
39 Pharmaceutical Review: Chinese medicine law was successfully promulgated at the end of last year, has become a major event in the Chinese medicine industry and even the Chinese nation, the national populism, national medicine has the protection of the law. Under the impetus of the policy, there is great room for the development of Chinese medicine. However, the Chinese medicine industry is faced with low concentration, serious damage to wild Chinese herbal medicine resources, and the decline in the quality of some chinese herbal medicines. Chinese medicine to the world is facing constraints and barriers, governance system and governance capacity modernization level needs to be improved, the urgent need to strengthen the top-level design and overall planning. 10, biopharmaceuticals, accelerate the cultivation and expansion of emerging industries
accelerate the cultivation and expansion of new industries. We will fully implement the strategic emerging industry development plan, accelerate the research and development and transformation of new materials, artificial intelligence, integrated circuits, biopharmaceuticals, fifth-generation mobile communications and other technologies, and become bigger and stronger industrial clusters.
39 Pharmaceutical Review: The 13th Five-Year Plan for the Development of the Bio-Industry proposes that by 2020, the size of the bio-industry will reach 8 trillion to 10 trillion yuan, with value added accounting for more than 4% of GDP, double the 3.5 trillion yuan in 2015.
"Plan" requires the scale of the biological industry to reach a compound annual growth rate of about 20%, significantly higher than the average growth rate of the pharmaceutical industry, in the pharmaceutical industry as a whole into the new normal of slowing growth, in line with the direction of innovation of biomedicine will undoubtedly become the focus of development. Policy East Wind Xi blowing, the biopharmaceutical industry should seize the opportunity to continuously carry out technological innovation to promote the rapid and healthy development of the biopharmaceutical industry. 11, the whole supervision
food and drug safety is related to people's health, must be strict and strict. We should improve the supervision system mechanism, enrich the supervision force at the grass-roots level, consolidate the responsibilities of all parties, adhere to the source control, production and management, and re-regulate disorder, and resolutely put the people's diet and drug safety at every pass.
39 Pharmaceutical Review: At present, China's drug, medical device safety is still in the high-risk period and contradictions highlighted period. Whether it's repeatedly banned "poison capsules", several exposures of the problem vaccine, or the ensuing drug safety problems have repeatedly stimulated the fragile social nerves. At present, there are a number of well-known large-scale pharmaceutical enterprises, listed companies in arrow, confiscated certificates. Based on data analysis and scientific research, the regulatory authorities can strengthen the importance of drug manufacturers on product quality, cold chain transportation chain, supply chain and other issues, so as to avoid the recurrence of popular drug problems such as vaccines, new drugs and special effects drugs. So now, pharmaceutical companies have to be careful! In order to avoid being investigated, pharmaceutical companies need to rely on industry self-discipline, under the pressure of flight inspection to develop the production process, warehousing, technology and other links to control the habits.
many policy dividends are being released to the pharmaceutical industry chain, the industry development of the "wind mouth" is forming, but in this "wind mouth" based, more test is the wisdom of pharmaceutical companies. In the view of 39 pharmaceutical jun, the future development of pharmaceutical enterprises, on the one hand, to target the masses urgently need to strengthen the original research drugs, first imitation drugs and other research and development innovation, accelerate cancer, diabetes, cardiovascular diseases and other major drugs with multiple and rare diseases; (39 drugs)